Fig. 7: Monotherapy and combination modulated expression of CD34, α-SMA, Ki-67, and PD-L1 in RLPS PDX. | Cell Death Discovery

Fig. 7: Monotherapy and combination modulated expression of CD34, α-SMA, Ki-67, and PD-L1 in RLPS PDX.

From: Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress

Fig. 7

CD34 labeled micro-vessels were decreased in the anlotinib and the combination group. α-SMA labeled CAFs were reduced in the combination group. Ki-67 is an indicator of proliferation, and it was reduced in the monotherapy group and further diminished in the combination group. PD-L1 was upregulated upon eribulin treatment, while a combination regimen reduced PD-L1 overexpression.

Back to article page